Study of Cytokine Filtration to Improve Outcomes in Adults Undergoing Double Lung Transplantation

What this Trial Is About

This research aims to evaluate the use of cytokine filtration during lung transplantation to improve outcomes for patients with irreversible end-stage lung disease. Lung transplantation remains the best treatment for these patients, but survival rates are low due to complications like primary graft dysfunction PGD occurring within 72 hours after transplant and chronic lung allograft dysfunction CLAD developing within 3 to 5 years. There is currently a lack of effective treatments for PGD and CLAD, making prevention crucial for patient survival. The study compares patients undergoing lung transplantation who receive treatment with a cytokine adsorption device called CytoSorb to those who undergo transplantation without this additional intervention. Cytokine adsorption aims to reduce harmful inflammatory molecules that contribute to PGD. Participants are randomly assigned to either receive the cytokine filtration device during transplantation or receive no additional treatment. The study collects preliminary data to assess the devices effects. Participants will be monitored closely during the first 72 hours after transplantation to measure oxygen levels, inflammatory markers, lung infiltrates and edema, blood gas measures, and severity and incidence of PGD. Longer-term follow-up over four years will evaluate lung function, episodes of acute rejection, chest CT scans, presence of CLAD, kidney function, mortality, and quality of life. The total study duration extends up to the end of 2029, with regular assessments to understand the impact of cytokine filtration on transplant outcomes.

Cytokine Filtration in Lung Transplantation: A Swedish National Study (GLUSorb)